tirzepatide surmount-1 weight loss percent nejm 2022 Semaglutide vs. for Obesity Tirzepatide and Hair Loss: Causes,

BMC Genomics 25, 283

A doctor can assess: BMI Medical history Blood sugar and metabolic markers Current medications Contraindications Side effect risk Follow-up needs The FDA has approved tirzepatide for chronic weight management in adults with obesity or overweight with at least one weight-related condition, alongside reduced-calorie diet and increased physical activity

What it is not: a replacement for a GLP-1 medication, and not a treatment for stress, appetite, or any medical condition

Existing literature indicates that GLP-1R agonists also suppress reinstatement for cocaine (56), nicotine (57), and opioids (58), further supporting a potential effect on relapse-like behaviors

For this reason the terms HDN and NNJ cannot be regarded as interchangeable, at least in the context of G6PD deficiency